This week we’re joined by Prof. Peter Rossing to discuss an evolving case covering glycemic control, target setting, and development of complications. Prof. Rossing is head of complications research at Steno Diabetes Center Copenhagen, professor of endocrinology at the University of Copenhagen, and an author of the ADA/EASD consensus report on the management of hyperglycemia in type 2 diabetes.

We’ve got a new website! Find it at diabetes.knowledgeintopractice.com, where you can see all past episodes of the podcast as well as other free CME resources. Follow us on Twitter (@dkipractice) or connect on LinkedIn.

Disclosures:

Prof. Rossing discloses the following:  

Advisor (fee to institution) - Astra Zeneca, Astellas, Bayer, Novo Nordisk, Gilead, Vifor, Boehringer Ingelheim, Eli Lilly, Sanofi

Research grant to Institution - Astra Zeneca, Novo Nordisk

All conflicts of interest have been mitigated prior to this activity.

Target Audience

This educational activity is intended for an international audience of non-US and non-UK HCPs.

Funding statement:

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.